BLASUBCUTANEOUSINJECTABLE
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
4/8 — Partial
LEQEMBI IQLIK (lecanemab-irmb) by Eisai is amyloid beta-directed antibody interactions [moa]. Approved for amyloid beta-directed antibody [epc]. First approved in 2025.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEQEMBI IQLIK (lecanemab-irmb) is a subcutaneous formulation of an amyloid beta-directed monoclonal antibody approved August 2025 for early cognitive decline due to Alzheimer's disease. It works by binding to amyloid beta protofibrils, slowing cognitive decline in early symptomatic disease. This is the subcutaneous variant of the original intravenous LEQEMBI, offering improved patient convenience and potentially broader uptake.
Launch
Early-stage launch with moderate competitive pressure (30/100) suggests growing commercial opportunity but rapid market maturation expected as dosing and access pathways stabilize.
Mechanism of Action
Amyloid Beta-directed Antibody Interactions
Pharmacologic Class:
Amyloid Beta-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LEQEMBI IQLIK offers exposure to a high-profile Alzheimer's therapeutic at launch, with roles spanning commercial execution, payer negotiation, and physician/patient education in a competitive but defined market. Career value is strongest for professionals seeking experience in rare disease, specialty biologic launch, and neurology franchise building within Eisai.
Brand Manager
Worked on LEQEMBI IQLIK at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.